MODERN THERAPY OF TYPE 2 DIABETES MELLITUS USING PHARMACOECONOMIC ANALYSIS

Authors

  • Kravchun N. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv
  • Karachentsev Yu. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv https://orcid.org/0000-0003-1317-6999
  • Kozakov O. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv https://orcid.org/0000-0003-4774-7278
  • Romanova I. P. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv
  • Cherniavskaya I. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv https://orcid.org/0000-0002-4834-3972
  • Karamyshev D. V. National University of Pharmacy, Kharkiv
  • Nemchenko A. S. National University of Pharmacy, Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2011.3.01

Keywords:

type 2 diabetes mellitus, treatment, tripride, pharmacoeconomics

Abstract

he clinical efficacy of Tripride was studied by pharmacoeconomic analysis. It was found that the appointment of the drug Tripride reduces the level of glycosylated hemoglobin as well as the simultaneous appointment of three drugs, and requires less material costs. Tripride also helps to improve lipid metabolism and reduce body weight.

References

Фармакоэкономическое моделирование отдаленных результатов лечения сахарного диабета 2 типа у пациентов, получавших современные аналоги инсулина по сравнению с терапией пероральными сахароснижающими препаратами [Текст]

/ И. И. Дедов, М. В. Шестакова, Ю. И. Сунцов [и др.] // Сахарный диабет. — 2010. — № 1. — С. 3–11.

Effect of a multifactorial intervention on mortality in type 2 diabetes [Text] / P. Gaede, H. Lund-Andersen, H. H. Parving, O. Pedersen // N. Engl. J. Med. — 2008. — Vol. 358. — P. 580–591.

10-year follow-up of intensive glucose control in type 2 diabetes [Text] / R. R. Holman, S. K. Paul, M. A. Bethel [et al.] // N. Engl. J. Med. — 2008. — Vol. 359. — P. 1577–1589.

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [Text] / J. S. Skyler, R. Bergenstal, J. Buse [et al.] // Diabetes Care. — 2009. — Vol. 32. — P. 187–192.

AACE/ACE Consensus Statement, Glycemic Control Algorithm [Text] // Endocr. Pract. — 2009. — Vol. 15, № 6. — P. 545.

Экономика диабета и диабетической помощи [Текст] / под ред. В. Грубера, Т. Ландер, Б. Лиз [и др.] пер. с англ. Н. Бондаренко. — М.: АРТ-БИЗНЕС-ЦЕНТР, 1999. — 128 с.

Шибаева, А. Сахарный диабет: все об эффективном и экономически обоснованном лечении. Часть 2 [Текст] / А. Шибаева // Аптека. — 2011. — № 27 (798). — С. 8–9.

Downloads

Published

2011-09-27

How to Cite

Kravchun, N. A., Karachentsev, Y., Kozakov, A., Romanova, I. P., Cherniavskaya, I., Karamyshev, D. V., & Nemchenko, A. S. (2011). MODERN THERAPY OF TYPE 2 DIABETES MELLITUS USING PHARMACOECONOMIC ANALYSIS. Problems of Endocrine Pathology, 37(3), 5-10. https://doi.org/10.21856/j-PEP.2011.3.01

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 5 6 > >>